Search
forLearn
5 / 801 resultslearn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn Niacinamide
learn oleanolic acid
learn pyrrolidone carboxylic acid
Research
5 / 350 results
research Acneiform Rash Caused by an Unlikely Drug: Topiramate
A man got a rare rash from the drug topiramate, which went away after he stopped taking it.
research Enoxaparin-induced alopecia in patients with cerebral venous thrombosis
Some patients lost hair after being treated with the drug enoxaparin for a brain vein clot.
research Hot Flashes in a Young Girl: A Wake-up Call Concerning Serenoa repens Use in Children
Serenoa repens (saw palmetto) may cause side effects like hot flashes in children and needs more research for safety in pediatric use.
research Mirtazapine-induced Gynecomastia: An Unknown Side Effect?
Mirtazapine can cause male breast enlargement.
research HAIR LOSS ASSOCIATED WITH ESCITALOPRAM: DO SSRIs AFFECT MELATONIN AT THE HAIR FOLLICLE?
The antidepressant escitalopram likely caused hair loss in a patient.
Community Join
5 / 1000+ resultscommunity RU58481, are side effects exegerated?
community Alfatradiol 1% study rebuttal.
community Extreme caution: my experience using Ru58841 only once
An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.
community Doubtful of RU58441's negative effects
RU58841's potential side effects, particularly heart palpitations, are debated, with some attributing them to contamination with minoxidil. Users report mixed experiences, with some seeing no side effects and others cautioning about the lack of reliable data on RU58841's safety.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.